[1]彭少怡,郭献飞,苏国海.降压药物对癌症的影响[J].国际心血管病杂志,2023,02:95-98,112.
点击复制
降压药物对癌症的影响(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2023年02期
- 页码:
- 95-98,112
- 栏目:
- 综述
- 出版日期:
- 2023-03-20
文章信息/Info
- Title:
- -
- Author(s):
- -
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2023.02.009
- 文献标识码:
- -
- 摘要:
- 高血压和癌症存在多种共同的影响因素，动脉高压是癌症患者最常见的心血管 危险因素，抗肿瘤治疗常导致动脉高压。抗高血压药物与癌症的关系仍不明确，抗高血压药 物可能对癌症发生、复发、癌症相关并发症和死亡率有负面影响，也可能降低癌症患者的死 亡率。该文对降压药物和癌症之间的关系进行探讨。
- Abstract:
- -
参考文献/References
[1] Narayan V, Thompson EW, Demissei B, et al. Mechanistic
biomarkers informative of both cancer and cardiovascular
disease: JACC State-of-the-Art review[J]. J Am Coll Cardiol,
2020, 75(21):2726-2737.
[2] Ma?yszko J, Ma?yszko M, Kozlowski L, et al. Hypertension
in malignancy—an underappreciated problem[J]. Oncotarget,
2018, 9(29):20855-20871.
[3] Ishikane S, Takahashi-Yanaga FM. The role of angiotensin Ⅱ
in cancer metastasis: Potential of renin-angiotensin system
blockade as a treatment for cancer metastasis[J]. Biochem
Pharmacol, 2018, 151:96-103.
[4] Wu CN, Wu SC, Chen WC, et al. AngiotensinⅡreceptor
blockers and oral squamous cell carcinoma survival:a
propensity-score-matched cohort study[J]. PLoS One, 2021,
16(12):e0260772.
[5] Santala EEE, Kotsar A, Veitonm?ki T, et al. Risk of urothelial
cancer death among People using antihypertensive drugs—a
cohort study from Finland[J]. Scand J Urol, 2019, 53(4):185-
192.
[6] Cheung KS, Chan EW, Seto WK, et al. ACE (angiotensinconverting
enzyme) inhibitors/angiotensin receptor blockers
are associated with lower colorectal cancer risk: a territorywide
study with propensity score analysis[J]. Hypertension,
2020, 76(3):968-975.
[7] 龙林竞, 曹国丽, 李玉婷, 等. 血管紧张素转换酶抑制剂/血
管紧张素受体拮抗剂治疗与消化系统肿瘤关系的Meta分析
[J]. 中国循证医学杂志, 2017, 17(9):1051-1059.
[8] Smith L, Parris C, Veronese N, et al. Cross-sectional
associations between angiotensin-converting enzyme inhibitor
use and cancer diagnosis in US adults[J]. Clin Exp Med, 2020,
20(3):409-416.
[9] Dakoutrou M, Alexopoulos A, Miligkos M, et al. Atenolol
treatment for severe infantile hemangiomas: comparison with
a propranolol group of our centre[J]. J Eur Acad Dermatol
Venereol, 2019, 33(5):e199-e200.
[10] Hicks BM, Filion KB, Yin H, et al. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based
cohort study[J]. BMJ, 2018, 363:k4209.
[11] Cronin-Fenton D. Angiotensin converting enzyme inhibitors
and lung cancer[J]. BMJ, 2018, 363:k4337.
[12] Jung MH, Lee JH, Lee CJ, et al. Effect of angiotensin receptor
blockers on the development of cancer: a nationwide cohort
study in Korea[J]. J Clin Hypertens (Greenwich), 2021,
23(4):879-887.
[13] Cao L, Zhang S, Jia CM, et al. Antihypertensive drugs use and
the risk of prostate cancer: a meta-analysis of 21 observational
studies[J]. BMC Urol, 2018, 18(1):17.
[14] Copland E, Canoy D, Nazarzadeh M, et al. Antihypertensive
treatment and risk of cancer: an individual participant data
meta-analysis[J]. Lancet Oncol, 2021, 22(4):558-570.
[15] Wang ZS, White DL, Hoogeveen R, et al. Anti-hypertensive
medication use, soluble receptor for glycation end products
and risk of pancreatic cancer in the women's health initiative
study[J]. J Clin Med, 2018, 7(8):197.
[16] Wijarnpreecha K, Li F, Xiang Y, et al. Nonselective betablockers
are associated with a lower risk of hepatocellular
carcinoma among cirrhotic patients in the United States[J].
Aliment Pharmacol Ther, 2021, 54(4):481-492.
[17] Lu K, Bhat M, Peters S, et al. Suppression of beta 2 adrenergic
receptor actions prevent UVB mediated cutaneous squamous
cell tumorigenesis through inhibition of VEGF-A induced
angiogenesis[J]. Mol Carcinog, 2021, 60(3):172-178.
[18] Cecilio HP, Valente VB, Pereira KM, et al. Beta-adrenergic
blocker inhibits oral carcinogenesis and reduces tumor
invasion[J]. Cancer Chemother Pharmacol, 2020, 86(5):681-
686.
[19] Mravec B, Horvathova L, Hunakova L. Neurobiology of
cancer: the role of β-Adrenergic receptor signaling in various
tumor environments[J]. Int J Mol Sci, 2020, 21(21):7958.
[20] Zhao Y, Wang QY, Zhao X, et al. Effect of antihypertensive
drugs on breast cancer risk in female hypertensive patients:
Evidence from observational studies[J]. Clin Exp Hypertens,
2018, 40(1):22-27.
[21] Farrugia MK, Ma SJ, Mattson DM, et al. Concurrent β-blocker
use is associated with improved outcome in esophageal cancer
patients who undergo chemoradiation: a retrospective matchedpair
analysis[J]. Am J Clin Oncol, 2020, 43(12):889-894.
[22] Bustamante P, Miyamoto D, Goyeneche A, et al. Betablockers
exert potent anti-tumor effects in cutaneous and uveal
melanoma[J]. Cancer Med, 2019, 8(17):7265-7277.
[23] Ahl R, Matthiessen P, Fang X, et al. β-blockade in rectal
cancer surgery: a simple measure of improving outcomes[J].
Ann Surg, 2020, 271(1):140-146.
[24] Morales DR, Pacurariu A, Slattery J, et al. Association
between hydrochlorothiazide exposure and different incident
skin, lip and oral cavity cancers: a series of population-based
nested case-control studies[J]. Br J Clin Pharmacol, 2020,
86(7):1336-1345.
[25] Su KA, Habel LA, Achacoso NS, et al. Photosensitizing
antihypertensive drug use and risk of cutaneous squamous cell
carcinoma[J]. Br J Dermatol, 2018, 179(5):1088-1094.
[26] Lei Z, Yang WY, Zuo Y. Beta-blocker and survival in patients
with lung cancer: a meta-analysis[J]. PLoS One, 2021,
16(2):e0245773.
[27] Li CR, Li T, Tang RW, et al. β-Blocker use is not associated
with improved clinical outcomes in women with breast cancer:
a meta-analysis[J]. Biosci Rep, 2020, 40(6):BSR20200721.
[28] Colt JS, Hofmann JN, Schwartz K, et al. Antihypertensive
medication use and risk of renal cell carcinoma[J]. Cancer
Causes Control, 2017, 28(4):289-297.
[29] Yang H, Yu YH, Hu XP, et al. Association between the overall
risk of prostate cancer and use of calcium channel blockers:
a systematic review and meta-analysis[J]. Clin Ther, 2020,
42(9):1715-1727.e2.
[30] Rotshild V, Azoulay L, Feldhamer I, et al. calcium channel
blockers and the risk for lung cancer: a population-based
nested case-control study[J]. Ann Pharmacother, 2019,
53(5):445-452.
[31] Lee H, Kim JW, Kim DK, et al. Calcium channels as novel
therapeutic targets for ovarian cancer stem cells[J]. Int J Mol
Sci, 2020, 21(7):2327.
[32] 周程, 汪光亮, 潘光玉, 等. 硝苯地平促进肝癌细胞Huh-7
自噬小体形成并上调Beclin1的表达[J]. 中国药理学通报,
2022, 38(2):228-233.
[33] Cho MA, Jeong SY, Sohn I, et al. Impact of angiotensin
receptor blockers, beta blockers, calcium channel blockers and
thiazide diuretics on survival of ovarian cancer patients[J].
Cancer Res Treat, 2020, 52(2):645-654.
[34] Busby J, Mills K, Zhang SD, et al. Postdiagnostic calcium
channel blocker use and breast cancer mortality: a populationbased
cohort study[J]. Epidemiology, 2018, 29(3):407-413.
[35] Brasky TM, Krok-Schoen JL, Liu JM, et al. Use of calcium
channel blockers and breast cancer risk in the women's health
initiative[J]. Cancer Epidemiol Biomarkers Prev, 2017,
26(8):1345-1348.
[36] Potteg?rd A, Pedersen SA, Schmidt SAJ, et al. Association of
hydrochlorothiazide use and risk of malignant melanoma[J].
JAMA Intern Med, 2018, 178(8):1120-1122.
[37] Wi l l iams NM, Vincent LT, Rodriguez GA, et al .
Antihypertensives and melanoma: an updated review[J].
Pigment Cell Melanoma Res, 2020, 33(6):806-813.
[38] Potteg?rd A, Hallas J, Olesen M, et al. Hydrochlorothiazide
use is strongly associated with risk of lip cancer[J]. J Intern
Med, 2017, 282(4):322-331.
[39] Adalsteinsson JA, Muzumdar S, Waldman R, et al.
Association between hydrochlorothiazide and the risk of in
situ and invasive squamous cell skin carcinoma and basal cell
carcinoma: A population-based case-control study[J]. J Am
Acad Dermatol, 2021, 84(3):669-675.
[40] Beckmann K, Garmo H, Lindahl B, et al. Spironolactone use
is associated with lower prostate cancer risk: a populationwide
case-control study[J]. Prostate Cancer Prostatic Dis,
2020, 23(3):527-533.
[41] Hiebert BM, Janzen BW, Sanjanwala RM, et al. Impact of
spironolactone exposure on prostate cancer incidence amongst
men with heart failure: a Pharmacoepidemiological study[J].
Br J Clin Pharmacol, 2021, 87(4):1801-1813.
[42] Wei C, Bovonratwet P, Gu A, et al. Spironolactone use does
not increase the risk of female breast cancer recurrence:
a retrospective analysis[J]. J Am Acad Dermatol, 2020,
83(4):1021-1027.
[43] Liu PP, McMenamin ?C, Spence AD, et al. Furosemide use
and survival in patients with esophageal or gastric cancer:
a population-based cohort study[J]. BMC Cancer, 2019,
19(1):1017.
备注/Memo
- 备注/Memo:
- 通信作者：苏国海， E-mail：gttstg@163.com
常用功能
统计/Statistics
- 摘要浏览/Viewed2
- 全文下载/Downloads199
- 评论/Comments
